Provigil (Modafinil) and Finasteride Interaction: What Clinicians and Patients Should Know
Modafinil is a wakefulness-promoting agent available under the brand name Provigil and also as the R-enantiomer armodafinil (Nuvigil). The FDA has approved it to treat narcolepsy, sleepiness related to obstructive sleep apnea, and shift-work disorder. Finasteride inhibits the enzyme 5-alpha reductase. It is marketed as Propecia (1 mg formulation) for androgenetic alopecia and as Proscar (5 mg formulation) for benign prostatic hyperplasia. While modafinil and finasteride do not have opposing pharmacodynamic effects, they both undergo metabolism via the liver enzyme CYP3A4, which is the sole basis for their interaction.
The direct answer: modafinil's FDA label identifies it as a moderate inducer of CYP3A4, and finasteride's FDA label states that finasteride is metabolized primarily by CYP3A4, so co-administration is pharmacologically plausible to lower finasteride blood levels over time. No dedicated pharmacokinetic study of the modafinil-finasteride pair has been published, no major interaction database rates the combination as contraindicated, and no case series describes clinical treatment failure attributed to this combination. This is an interaction that is mechanistically real but unquantified for this specific drug pair, which is a different situation than an interaction that has been measured and found small.
Why this pairing comes up in practice
Men taking finasteride for hair loss or prostate symptoms are a demographic that also uses modafinil off-label for cognitive support, or on-label for a diagnosed sleep disorder. The two prescriptions can land in the same chart without either prescriber flagging the other drug, because the interaction is not dramatic enough to appear on most default alert lists as a hard stop.
What is established
Two facts anchor this whole discussion, and both come from FDA-approved labeling rather than a specific interaction trial:
- Modafinil is described in its FDA prescribing information as inducing its own metabolism and that of other CYP3A4 substrates (modafinil label).
- Finasteride's FDA prescribing information states that finasteride is cleared primarily through CYP3A4-mediated hepatic metabolism.
Neither label names the other drug specifically. That absence is worth stating plainly: this is a class-level induction warning applied to a specific substrate, not a labeled drug-drug interaction with a stated magnitude.
What is pharmacologically plausible but not measured for this pair
CYP3A4 induction from modafinil has been studied against other substrates in the published literature, and those studies generally show that modafinil can meaningfully lower blood levels of some CYP3A4-dependent drugs, with the effect building over roughly two to four weeks as enzyme induction reaches steady state. It is reasonable to expect some reduction in finasteride exposure by the same mechanism. It is not established how large that reduction is for finasteride specifically, because finasteride's own pharmacokinetics differ from the substrates that have actually been tested: finasteride already has fairly high oral bioavailability and a metabolic profile that is not identical to more "sensitive" CYP3A4 substrates used in classic induction studies. Any specific percentage reduction in finasteride AUC that a source quotes for this pairing should be treated as an estimate requiring verification against a primary pharmacokinetic study, not as a settled figure. We are not restating a precise number here because none of the identifiers commonly cited for this claim could be confirmed as applying to modafinil and finasteride together.
What is not established
- Whether the magnitude of induction is clinically significant enough to cause measurable treatment failure in typical patients.
- Whether the effect differs meaningfully between the 1 mg alopecia dose and the 5 mg BPH dose (this is a plausible extrapolation from finasteride's known dose-response relationship, not a tested finding for this interaction).
- Whether armodafinil behaves identically to modafinil in this specific pairing. Armodafinil is the R-enantiomer of modafinil with a longer half-life and a similar general CYP3A4 induction profile, so the same caution likely applies, but this has not been separately studied against finasteride.
Evidence-status interaction assessment
| Claim | Status | Evidence anchor | What a clinician or pharmacist should verify |
|---|---|---|---|
| Modafinil induces CYP3A4 | Established, FDA-labeled | Modafinil FDA label | No verification needed for this general mechanism claim |
| Finasteride is metabolized primarily via CYP3A4 | Established, FDA-labeled | Finasteride FDA label | No verification needed for this general mechanism claim |
| Modafinil lowers blood levels of other CYP3A4 substrates | Established in general, drug-specific magnitude varies | Published induction literature (general) | Confirm the specific substrate and study before quoting a numeric effect size |
| Modafinil lowers finasteride levels by a specific percentage | Plausible, not established | No dedicated PK study identified | Do not cite a precise AUC reduction figure until a primary source is located and confirmed to be about this drug pair |
| This combination causes clinical treatment failure of finasteride | Not established | No case series identified | Ask whether the patient's specific symptom (rising PSA, hair shedding) has another explanation before attributing it to this interaction |
| Major interaction databases rate this combination as contraindicated | Not the case as commonly summarized | General database classification practice | Check the current entry in the clinician's own reference tool, since classifications can change and should be dated at the point of use |
| Serum DHT can help clarify whether 5-alpha reductase inhibition is adequate | Plausible clinical practice, supported by general 5-ARI pharmacology | General pharmacology of 5-alpha reductase inhibitors | Confirm local lab reference ranges and turnaround before relying on a single value |
What to monitor if both drugs are prescribed
A dose increase or drug switch is not the default response. A stepwise, symptom-driven approach fits the strength of the evidence better than a blanket adjustment:
- Document the combination. Note in the chart that the patient is on both drugs and that a modest reduction in finasteride effect is mechanistically plausible.
- Track the outcome finasteride was prescribed for. For BPH, that means PSA and urinary symptom scores at the usual follow-up intervals. For alopecia, that means the patient's own report of shedding or regrowth, ideally supported by photographs at consistent intervals.
- Escalate to lab testing only if the clinical picture changes. A serum DHT level, drawn and interpreted by the prescriber, can help distinguish reduced drug effect from an unrelated cause of symptom change.
- Reserve dose or drug changes for documented non-response. Any change to finasteride dosing or a switch to dutasteride should be made by the prescriber based on the individual patient's clinical course, not applied automatically because modafinil was added.
This article does not provide an individualized dosing recommendation. Any change to finasteride or modafinil dosing should be made by the prescriber managing the patient, based on that patient's labs, symptoms, and other medications.
When this combination needs closer attention or specialist input
There is no absolute contraindication between modafinil and finasteride, and the combination does not carry known additive toxicity, QT-interval risk, or serotonin syndrome risk. Situations that warrant more attentive follow-up rather than avoidance include:
- A patient who has previously failed finasteride therapy and is retrying it, where any further reduction in exposure carries more downside.
- A patient on multiple other CYP3A4-dependent medications, where the cumulative induction effect across drugs is harder to predict than any single pairing.
- A patient reporting new sexual side effects after starting either drug. Finasteride carries an FDA-acknowledged risk of decreased libido and erectile dysfunction in a minority of users, and modafinil can independently affect libido in some patients. Distinguishing which drug is responsible requires a careful history rather than an assumption based on the interaction discussed here.
Seek prompt medical attention rather than trying to sort out a drug interaction independently if a patient develops signs of a serious reaction to either drug on its own, such as a significant mood or behavior change on modafinil, or a severe or persistent new symptom after starting either medication.
Other modafinil enzyme effects worth knowing
Modafinil's effect on drug-metabolizing enzymes is not limited to CYP3A4 induction. Its label also describes inhibition of CYP2C19, which can raise levels of some other medications cleared through that pathway. Patients taking modafinil alongside other CYP2C19-dependent drugs should have that combination reviewed on its own terms rather than assuming the finasteride discussion above applies.
Evidence boundary
What is established: modafinil is an FDA-labeled CYP3A4 inducer, and finasteride is an FDA-labeled CYP3A4 substrate. What is plausible but unproven: that this shared pathway meaningfully lowers finasteride blood levels in a way that could affect prostate or hair-loss treatment outcomes for some patients. What is not established: the actual magnitude of that effect in humans taking this specific combination, and whether it causes measurable clinical failure. Readers and clinicians should treat any specific percentage attached to this interaction as an estimate pending confirmation from a dedicated pharmacokinetic study, and should rely on clinical monitoring of the outcome finasteride was prescribed for rather than on a number that has not been verified against primary literature.
References
- PROVIGIL (modafinil) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037s038lbl.pdf
- NUVIGIL (armodafinil) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf
Note for editorial and medical review: the source draft attached specific PMIDs, numeric effect sizes (including a 20-40% AUC reduction figure, a triazolam induction magnitude, phase III alopecia hair-count numbers, PCPT trial figures, and a PLESS/PROSPECT prostate-volume figure) and two named-physician quotations to this topic. None of these identifiers could be confirmed as matching the underlying claim through the discovery process for this draft, and the quotations lack a verifiable primary source. They have been removed or generalized rather than carried forward. Before publication, a reviewer with database access should confirm whether a specific, on-topic pharmacokinetic study of modafinil and finasteride exists and, if so, reintroduce a precise figure with the correct citation.